Navigation Links
MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma
Date:7/22/2010

SAN DIEGO, July 22 /PRNewswire/ -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that the first patients have been enrolled in a Phase II clinical trial aimed at assessing the efficacy and safety of its vaccine to prevent or delay the recurrence of sarcoma. The clinical trial will enroll 126 metastatic sarcoma patients, 16 years or older in a randomized, multicenter, double-blind Phase II study of a trivalent vaccine specifically developed to target and kill residual circulating cancer cells and micrometastases thought to cause recurrent cancer.  

In the United States (US), there are approximately 13,200 sarcoma cases diagnosed each year, representing less than 1% of all new cancers.  Prognosis remains poor, with more than 5,200 patients in the US dying of disease each year.  As in other malignancies, disease recurrence and metastasis are common in sarcoma.  Despite undergoing potentially curative surgical resection or combination therapy, the majority of these patients with recurrent sarcoma die as a result of further recurrences.  The addition of chemotherapy to surgical resection has not shown to improve outcome in adult patients with sarcoma. Thus, in the majority of cases, the current standard of care following treatment of metastatic disease and the achievement of disease-free status is expectant management.

The vaccine is a trivalent ganglioside vaccine administered with an immunological adjuvant in a series of 10 subcutaneous injections given over an 84-week period.  The vaccine is intended to instruct the patient's immune system to make antibodies against the three ganglioside ant
'/>"/>

SOURCE MabVax Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014  SI-BONE, Inc., a medical ... System, ® a minimally invasive surgical (MIS) device indicated ... today announced the expansion of its European operations with the ... Eric Schaber as General Manager, Germany.  Mr. Schaber will ... president of Europe , Middle ...
(Date:10/1/2014)... -- CVS Health is thanking its 26,000 pharmacists during October,s ... way health care is delivered to increase access, lower ... mail service pharmacies and specialty pharmacies nationwide.  ... CVS Health to reflect our broader health care commitment ... shape the future of health," said Larry Merlo ...
(Date:10/1/2014)... October 1, 2014 Sophia Genetics, ... Sequencing (NGS) data analysis, today launches a unique CFTR ... analysis in a single NGS experiment. The CE-IVD marked ... of variants in a single NGS experiment with clinical ... not been possible to simultaneously analyse all relevant CFTR ...
Breaking Medicine Technology:SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2
... (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO)Q2 2011 Change on a , ... exchange rates(1) , H1 2011Change on a , ... , exchange ratesNet sales , euro 8,349m+0.5% , +6.9% , ... , -7.0% , euro 4,320m-11.9% , -11.5%Business EPS (1) , ...
... 2011 Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ ... develop its late stage oncology pipeline to market coupled with ... 2011. "In the second quarter, we seized on ... of New Drugs ("OND") in allowing us to resubmit the ...
Cached Medicine Technology:Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 2Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 3Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 4Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 5Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 6Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 7Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 8Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 9Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 10Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 11Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 12Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 13Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 14Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 15Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 16Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 17Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 18Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 19Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 20Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 21Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 22Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 23Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 24Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 25Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 26Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 27Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 28Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 29Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 30Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 31Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 32Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms 33Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 2Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 3Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market 4
(Date:10/2/2014)... FLORIDA (PRWEB) October 02, 2014 ... Accredited teleradiology and telemedicine solutions provider including its ... Lorna Backhaus have joined its Executive Team as ... respectively. , Brent Backhaus, USARAD’s new President and ... 25 years of progressively responsible experience in commercial-, ...
(Date:10/2/2014)... Birmingham, Ala. (PRWEB) October 02, 2014 ... Construction awards from the Associated Builders and Contractors ... following projects at tonight’s banquet held at Sheraton ... of Western Massachusetts, Healthcare $10 Million to $25 ... Benning: Love Dental Clinic, Federal Government $10 Million ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, ... a neurotic personality style and prolonged stress may have ... suggests. Tracking 800 women over nearly four decades, ... jealous and moody -- which they defined as neurotic ... of developing Alzheimer,s compared to women scoring lowest in ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... of developing celiac disease isn,t reduced by breast-feeding. Nor will ... gluten to an infant,s diet help prevent celiac disease. ... studies in the Oct. 2 New England Journal of ... that a child could avoid celiac disease if mothers breast-feed ...
(Date:10/1/2014)... from the University of Adelaide have developed a model ... a good outcome from treatment - from their very ... a range of factors, including clinical symptoms, cognitive abilities, ... the patient,s blood. , Speaking in the lead up ... Head of Psychiatry , Professor Bernhard Baune ...
Breaking Medicine News(10 mins):Health News:Teleradiology and Telemedicine Pioneers Brent Backhaus and Lorna Backhaus Join USARAD Holdings, INC. & SecondOpinions.com® 2Health News:Teleradiology and Telemedicine Pioneers Brent Backhaus and Lorna Backhaus Join USARAD Holdings, INC. & SecondOpinions.com® 3Health News:Robins & Morton wins nine awards from Associated Builders and Contractors 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Predicting the future course of psychotic illness 2
... Regardless of your level of,expertise, you will have a ... product development. Do you know: The essential DNA ... organic growth? How to exploit process and quality for ... excellence framework? How to achieve product innovation excellence? ...
... WESTLAKE VILLAGE, Calif., Sept. 13 Hackensack,University ... hospital located,in Hackensack, N.J., and affiliated with ... Jersey-New Jersey Medical School, is the first ... patient experience in all,four service areas: inpatient, ...
... Single-digit percentage increases prove value of Basic and ... and,retirees can expect continuing reliability and value from ... Service Benefit Plan,(Federal Employee Program or FEP(R)) in ... in 2008 and premiums for,FEP BlueVisionSM will stay ...
... CAMBRIDGE, Mass.In work that could lead to new treatments ... phenomena of seeing better with one eye covered, MIT ... for binocular vision. , Unlike horses and eagles, whose ... different scenes, humans see a single, in-depth view. Now ...
... Sept. 13 Tyco,International Ltd. (NYSE: TYC , ... an increase in the company,s quarterly dividend to 15,cents ... The new quarterly,dividend represents a 36% increase over the ... indicated it expected to,pay following the separation of Tyco ...
... fillings , THURSDAY, Sept. 13 (HealthDay News) -- The ... to the dentist,s office, according to a team developing ... available to dentists and their relieved patients in the ... on a non-thermal plasma brush that uses a low-temperature ...
Cached Medicine News:Health News:Quality Innovators to Network in Atlanta Sept. 19-21: Learn from Those Who Got It Right 2Health News:J.D. Power and Associates Reports: Hackensack University Medical Center Recognized as First Hospital to Achieve Distinction for Providing an Outstanding Inpatient Experience in All Four Service Areas 2Health News:J.D. Power and Associates Reports: Hackensack University Medical Center Recognized as First Hospital to Achieve Distinction for Providing an Outstanding Inpatient Experience in All Four Service Areas 3Health News:Federal Employee Program Maintains Low Health Premiums In 2008 2Health News:Federal Employee Program Maintains Low Health Premiums In 2008 3Health News:MIT IDs binocular vision gene 2Health News:Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program 2Health News:Coming Soon: Pain-Free Dentistry 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: